Sign in
Not yet recruitingPhase 3

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset

Key facts

Who runs it
Tasly Biopharmaceuticals Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
978 people, planned
Starts
30 Nov 2026
Expected to end
1 Jun 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Recombinant Human Prourokinase for Injection (rhPro-UK)
  • Aspirin Enteric-Coated Tablets
  • Aspirin Enteric-Coated Tablet Placebo
  • rhPro-UK Placebo
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (35)Hide the full registry criteria

Who can take part

  • Age >=18 years, male or female
  • Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well
  • Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke
  • Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL)
  • NIHSS score of 6 to 25 (inclusive)
  • Pre-stroke mRS score <2
  • No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator)
  • The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form

Who cannot take part

  • Previous history of intracranial hemorrhage
  • Intracranial or intraspinal surgery within the past 3 months
  • Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator)
  • Treatment with low-molecular-weight heparin or heparin within 24 hours
  • Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours
  • Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products
  • Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.)
  • Major head trauma or ischemic stroke within the past 3 months
  • Gastrointestinal or urinary tract bleeding within the past 3 weeks
  • Active internal bleeding
  • Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg
  • Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance
  • Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis
  • Any terminal illness with a life expectancy of less than 1 year
  • Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial
  • Acute bleeding tendency, including platelet count <100 x 10\^9/L
  • Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7
  • Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL)
  • Severe renal insufficiency (eGFR <30 mL/min/1.73 m\^2)
  • Unable to complete CTP/CTA or PWI/DWI/MRA examination
  • Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory)
  • Intracranial tumor or giant intracranial aneurysm
  • Arterial puncture at a non-compressible site within the past 1 week
  • Aortic arch dissection
  • Bacterial endocarditis or pericarditis
  • Pregnant or lactating women
  • Participation in another clinical trial within the past 1 month

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Acute ischemic stroke AIS

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

The 2 groups in the trial

  • rhPro-UK GroupTreatment being tested

    Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

    Treatment: Recombinant Human Prourokinase for Injection (rhPro-UK) and Aspirin Enteric-Coated Tablet Placebo

  • Standard of Care (SOC) GroupExisting treatment, for comparison

    Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

    Treatment: Aspirin Enteric-Coated Tablets and rhPro-UK Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset
Criteria questions
Built from NCT07942584, who can take part
Record updated
17 November 2026